Şunu aradınız:: nonpegylated (İngilizce - Maltaca)

the plasma half-life of pegintron is prolonged compared with nonpegylated interferon alfa-2b.
il-half-life ta’ pegintron fil-plażma hija mtawla meta mqabbla ma’ interferon alfa-2b mhux pegilat.

2 (pegylated or nonpegylated) and ribavirin combination therapy or interferon alpha monotherapy (see section 5.1).
2 pegilata) u ribavirin f’ terapija kombinata jew b’ monoterapija b’ interferon alfa ma rnexxitx (ara sezzjoni 5. 1).

the potency of this product should not be compared to that of another pegylated or nonpegylated protein of the same therapeutic class (see section 5.1).
il-qawwa ta’ dan il-prodott m’għandhiex titqabbel ma’ dik ta’ proteina oħra pegilata jew mhux pegilata tal-istess klassi terapewtika (ara sezzjoni 5.1).

for patients with prior failure on therapy with nonpegylated interferon or pegylated interferon and negative at week 12, the sustained response rates were 59 % and 50 %, respectively.
għall-pazjenti li ma kinux irnexxew b’terapija li ngħatat qabel b’interferon mhux pegilat jew interferon pegilat u negattivi f’ġimgħa 12, ir-rati ta’ rispons sostnut kienu ta’ 59 % u 50 %, rispettivament.

in combination with peginterferon alfa-2b in adults who have failed previous treatment with interferon alpha (pegylated or nonpegylated) and ribavirin combination therapy or interferon alpha monotherapy.
f’ kombinazzjoi ma ’ peginterferon alfa- 2b f’ adulti li t- trattament li ngħatalhom qabel b’ interferon alfa (pegilat jew mhux pegilat) flimkien ma ’ ribavirin jew b’ monoterapija ta ’ interferon alfa kien falla.

20 non-responders to prior therapy with pegylated interferon alpha/ribavirin were less likely to achieve a week 12 response to retreatment than non-responders to nonpegylated interferon alpha/ribavirin (12.4% vs.
dawk li ma kellhomx rispons għat- terapija li ngħatat qabel b’ interferon alpha pegilat/ ribavirin kellhom anqas ċans li jiksbu rispons f’ Ġimgħa 12 għall- kura mill- ġdid minn dawk li ma kellhomx rispons għal interferon alpha mhux pegilat/ ribavirin (12% vs 28. 6%).